Redox-active nitroxides enhance cisplatin efficacy against cervical cancer.

ABSTRACT: Cisplatin remains the primary treatment for most cervical cancer cases, though its clinical efficacy is hindered by dose-dependent toxicity and incurring chemoresistance. The overexpression of the glucocorticoid receptor (GR) and cellular redox state is linked to increased resistance to chemotherapy in cervical cancer. This study explores the combinations of novel steroidal and nitroxide-based treatments to improve the efficacy of cisplatin against cervical cancer. Two lead nitroxide-functionalised prednisolone hybrids (CS91 and CS187) were identified for their potent anti-proliferative activity in multiple cervical squamous cell carcinoma (SCC) cell lines. These compounds exhibit comparable anti-proliferative activity to the parent nitroxides, while maintaining GR binding capability. When

SUBMITTER: Soltau CP 

PROVIDER: S-EPMC12808834 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature